ACVWith the Oak Group and Oculys acquisitions, the company has just over $8.2M in RECURRING revenue from now onward, and that is assuming 0% growth (which we know NOT to be the case).
$8.2M in recurring revenue.
Fully diluted share count is just over 177M, which includes warrants and options that would bring just over $10M CASH.
At 0.18, market cap is $31.8M.
Subtract $10M cash, plus approx. $3M cash on hand currently (post Oculys acquisition), and the stock is trading at 2 TIMES RECURRING REVENUE.
This does NOT account for any additional growth (organic or by acquisition).
And that excludes the NS deal, and any additional sales/licenses, non-recurring revenue, and selling additional VitalHub software to the current clients.
This is a DEEP value play at this point.
Do your own DD.